On this page
Batten disease (CLN1, infantile)
This condition affects the nervous system, causing developmental regression, vision loss, seizures, and motor decline typically starting during infancy or early toddlerhood. It belongs to a group of disorders called neuronal ceroid lipofuscinoses, characterised by abnormal accumulation of storage material in nerve cells throughout the body.
Available at Jeen Health
Clinical tests that include this
Overview
Infantile CLN1 Batten disease represents the earliest and most severe form of the neuronal ceroid lipofuscinoses, a family of inherited storage disorders affecting the nervous system. The condition typically becomes apparent when previously healthy infants begin to lose developmental skills they had acquired. This disorder stems from toxic accumulation of waste products inside cells throughout the nervous system, particularly affecting brain tissue. The name 'CLN1' refers to the specific genetic subtype, distinguishing it from other forms of Batten disease caused by variants in different genes. Although extremely rare, with exact UK prevalence not well established, the condition has profound impact on affected children and their families, as neurological decline is relentless.
Symptoms & clinical features
The clinical picture typically emerges during infancy or early toddlerhood, when parents or health visitors notice developmental regression. Early features often include loss of previously acquired motor skills such as sitting or walking, alongside emerging vision problems. Many children develop myoclonus, which appears as sudden involuntary muscle jerks, and this symptom can be particularly distressing for families to witness. Seizures frequently develop and may prove difficult to control with standard antiepileptic medications. Progressive vision loss occurs as the retina degenerates, typically leading to blindness during early childhood. As the condition advances, affected children lose the ability to interact with their environment, experience profound intellectual disability, and develop feeding difficulties requiring specialised nutritional support. Movement becomes increasingly impaired, with many children eventually losing all voluntary motor control.
Video: Genetics 101
Affected organs
The nervous system bears the primary burden of this condition, with widespread neurodegeneration affecting both the brain and retina. Brain tissue shows progressive atrophy on imaging studies, with characteristic changes visible on MRI scans as the condition advances. The retina undergoes specific degeneration, causing the vision loss that represents one of the earliest and most consistent features. At the cellular level, neurons throughout the central nervous system accumulate abnormal storage material called lipofuscin, which appears as distinctive patterns under electron microscopy. The nervous system sustains the most severe damage, although storage material may accumulate to a lesser degree in other tissues. This typically does not cause clinically significant problems outside the brain and eyes.
Risks & severity
Infantile CLN1 disease follows a severe and predictable course, with all affected children experiencing profound neurological deterioration. The prognosis is poor, with life expectancy substantially shortened. The condition does not show a milder spectrum - all children with biallelic pathogenic PPT1 variants develop the full infantile phenotype. Risk of recurrence in subsequent pregnancies for carrier parents is 25% with each conception, making genetic counselling essential for family planning. There is currently no variation in severity based on specific PPT1 variants; all pathogenic changes result in near-complete loss of enzyme function and similar clinical trajectories.
Genetic causes
Pathogenic variants in PPT1 disrupt production or function of palmitoyl-protein thioesterase 1, an enzyme critical for breaking down certain lipid-modified proteins within cellular compartments called lysosomes. Under normal circumstances, this enzyme cleaves fatty acid chains from other proteins, which enables their degradation and recycling within the cell. Loss of this enzymatic activity causes lipid-protein complexes to build up progressively inside lysosomes, creating the distinctive storage material visible in affected tissues. Neurons appear particularly vulnerable to this lysosomal dysfunction, sustaining toxic damage as storage material accumulates. Individuals require two working copies of PPT1 - one inherited from each parent - to maintain normal cellular housekeeping. When both gene copies carry pathogenic variants, enzyme activity falls below the critical threshold needed to prevent accumulation, triggering the disease cascade.
- PPT1 palmitoyl-protein thioesterase 1The PPT1 gene provides instructions for producing an enzyme called palmitoyl-protein thioesterase 1, which plays a crucial role in breaking down fats attached to proteins within cellular lysosomes.
Inheritance pattern
This condition follows autosomal recessive inheritance, meaning affected children inherit one non-working PPT1 gene copy from each parent. Parents are typically carriers - they possess one working and one non-working gene copy but show no symptoms themselves because one functional copy produces sufficient enzyme for normal health. When two carriers have children together, each pregnancy carries a 25% chance of producing an affected child, a 50% chance of producing a carrier child, and a 25% chance of producing a child with two working copies. Extended family members may also be carriers, particularly in communities where the parents share ancestry, making cascade carrier testing sometimes appropriate for reproductive planning.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis typically begins with clinical recognition of the characteristic pattern of developmental regression, vision loss, and seizures in a previously healthy infant. Brain MRI may show progressive cerebral and cerebellar atrophy. Definitive diagnosis requires demonstration of markedly reduced or absent PPT1 enzyme activity, which can be measured in blood samples or cultured skin cells. Genetic testing identifying biallelic pathogenic variants in PPT1 confirms the diagnosis and enables accurate genetic counselling. In the UK, suspected cases are referred through the NHS Genomic Medicine Service, with paediatric neurologists or clinical geneticists typically coordinating the diagnostic pathway. Some affected families receive their diagnosis following investigation of an affected older sibling, whilst others are identified through newborn screening programmes being piloted in certain jurisdictions, though this is not yet standard NHS practice.
Management & lifestyle
Management focuses on supportive care to optimise quality of life and minimise suffering, as no disease-modifying treatments are currently available. Seizure control requires specialist paediatric neurology input, often using multiple antiepileptic medications, though complete seizure freedom is rarely achieved. Nutritional support becomes essential as feeding difficulties progress, with many families facing decisions about gastrostomy tube placement. Physiotherapy and occupational therapy help maintain comfort and prevent complications of immobility. Families benefit enormously from access to specialist palliative care services, respite care, and support groups connecting them with others facing similar challenges. The NHS care pathway typically involves coordination between paediatric neurology, clinical genetics, palliative care, and community children's nursing teams. Genetic counselling supports families in understanding recurrence risks and reproductive options for future pregnancies, including prenatal diagnosis and preimplantation genetic testing.
UK care pathway
Within the NHS Genomic Medicine Service, infantile CLN1 disease falls under the Neurological and neurodevelopmental disorders panel (R78) and Early onset or syndromic epilepsy panel (R59), depending on presenting features. Referral to clinical genetics services typically occurs through paediatric neurology or general paediatrics when the characteristic clinical pattern is recognised. Genetic testing through the GMS pathway enables definitive molecular diagnosis and cascade testing for at-risk family members. Genetic counsellors provide essential support for families navigating the diagnosis, explaining inheritance patterns, discussing recurrence risks, and outlining reproductive options. Following diagnosis, families are typically linked with specialist multidisciplinary clinics that coordinate the complex care needs, alongside local community teams who deliver day-to-day support.
Frequently asked questions
Can anything slow down or stop the progression of infantile CLN1 disease?
Currently, no treatments can slow or halt disease progression in infantile CLN1 disease. Research into potential therapies including enzyme replacement and gene therapy is ongoing, but no approved disease-modifying treatments are available. Management focuses on symptom control and maximising quality of life.
If both parents are carriers, what are the chances our next child will be affected?
Each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier child, and a 25% chance of producing a child with two working gene copies. These probabilities remain the same for every pregnancy, regardless of previous outcomes.
How will we know if other family members are carriers?
Once pathogenic PPT1 variants are identified in an affected child, at-risk relatives can be offered carrier testing through clinical genetics services. Testing can clarify carrier status for siblings and other family members who may wish to know for reproductive planning purposes.
Are there options for having unaffected children in future pregnancies?
Carrier couples can access prenatal diagnosis during pregnancy through chorionic villus sampling or amniocentesis, or preimplantation genetic testing before embryo transfer during IVF. Genetic counsellors can discuss these options in detail, supporting families in making decisions aligned with their values and circumstances.
What support is available for families caring for a child with infantile CLN1 disease?
The NHS provides access to multidisciplinary care teams including paediatric neurology, palliative care specialists, community children's nurses, physiotherapists, and genetic counsellors. Families can also access respite care services and connect with support groups specifically for neuronal ceroid lipofuscinoses to share experiences with others facing similar challenges.